linjc16/ctgov huggingface dataset:
Can Hospital Acquired Pneumonia be Prevented in Patients Who Gurgle?

Study Overview
=================
Brief Summary
-----------------
Hospital inpatients who have gurgling sounds heard during speech or breathing have been observed to have a higher risk of hospital acquired pneumonia. Patients who gurgle and who consent to participation will be randomized to receive routine clinical management or management to include measures employed to reduce risks of aspiration, namely, 1. head of bed up (30 degrees or higher), 2. swallowing evaluation by speech therapist (and feeding predicated on formal evaluation), 3. prompting managing physicians to reduce sedating medications to minimal effective dose.

Official Title
-----------------
Can Hospital Acquired Pneumonia be Prevented in Patients Who Gurgle?

Conditions
-----------------
Hospital Acquired Pneumonia in Gurgling Patients

Intervention / Treatment
-----------------
* Other: Anti-gurgling intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gurglers who consent to participate Exclusion Criteria: Non-gurglers Patients presenting with pneumonia prior to identification with gurgling Patients receiving comfort-care-only

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Anti-gurgling intervention|1. head of bed 30 degrees or higher, 2. swallowing evaluation-based feeding, 3. sedatives titrated to minimal effective dose.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospital acquired pneumonia |  | 14 days (average) |
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.

Official Title
-----------------
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Conditions
-----------------
Hemodialysis Patients With Hyperphosphatemia

Intervention / Treatment
-----------------
* Drug: PA21


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Receiving stable maintenance hemodialysis 3 times a week. Dialysis patients with hyperphosphatemia Exclusion Criteria: Patients having history of a pronounced brain / cardiovascular disorder. Patients having severe gastrointestinal disorders. Patients having severe hepatic disorders.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PA21<br> | Drug: PA21<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Adverse Events |  | 52 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum Phosphorus Concentrations at End of Treatment (Actual Measured Value) |  | 52 weeks | 
| Corrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value) |  | 52 weeks | 
| Serum Intact-PTH Concentrations at End of Treatment (Actual Measured Value) |  | 52 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hemodialysis, Hyperphosphatemia
Allogeneic Cord Blood for Neurological Diseases in Adults

Study Overview
=================
Brief Summary
-----------------
This open label trial is conducted to investigate the efficacy and safety of allogeneic umbilical cord blood therapy for adult patients with neurological diseases.

Detailed Description
-----------------
Neurological diseases such as stroke or spinal cord injuries are very common etiologies causing disability in developed countries. Cord blood possess various stem and progenitor cells, as well as their secreted regenerative factors, and is known to repair injured brain. The investigators clinical research aims to determine the safety and efficacy of allogeneic Umbilical Cord Blood for adult patients with neurological diseases such as stroke and spinal cord injury.

Official Title
-----------------
Allogeneic Cord Blood in the Treatment of Neurological Diseases in Adults

Conditions
-----------------
Stroke, Neurological Diseases, Spinal Cord Injuries

Intervention / Treatment
-----------------
* Biological: Allogeneic cord blood treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ischemic or hemorrhagic stroke (onset < 24 months), or Spinal cord injury (onset < 24 months) Exclusion Criteria: Raised intracranial pressure Malignant cancer Renal failure Severe pulmonary dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: allogeneic cord blood for adult patients with neurological diseases
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Allogeneic cord blood therapy<br>Allogeneic cord blood therapy | Biological: Allogeneic cord blood treatment<br>* Allogeneic cord blood treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in modified Rankin Scale (mRS) | modified Rankin Scale (mRS) from 1 - 5 whereby 1 is best (no significant disability) and 5 is worst (severe disability); The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. | 1 month - 3 months - 6 months - 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Monitoring Adverse Events | Number of participants with treatment-related adverse events as assessedCommon by Toxicity Criteria for Adverse Events (CTCAE).version 5.0; adverse events are graded on a scale from 0 to 5, whereby grade 0 is best (no AE) and grade 5 is worst (fatal). | 1 month - 3 months - 6 months - 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adults
Consumption Status of Caffeine and Adverse Effects Experience Among Anesthetists

Study Overview
=================
Brief Summary
-----------------
High-caffeine consumption has been increasing in physicians, frequently causing the most common symptoms such as tremor, insomnia, anxiety, and nervousness and rarely leading to serious adverse effects like seizure, acute mania, and stroke due to caffeine overdose. There have been no studies regarding analysis of high-caffeine consumption and its adverse effects among anesthetists.

Detailed Description
-----------------
This study was to examine high-caffeine consumption patterns, associated factors, and adverse effects based on responses anesthetists with different age of experience.

Official Title
-----------------
Consumption Status of Caffeine and Adverse Effects Experience Among Anesthetists

Conditions
-----------------
Caffeine, Caffeine Withdrawal, Caffeine Dependence

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any anesthetist Exclusion Criteria: Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 24 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Survey|Prevalence of safe caffeine consumption among anesthetists|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The prevalence of caffeine consumption among a sample of anesthesiologists, to determine their caffeine daily intake in relation to the safe level suggested by the European Food Safety Authority (EFSA). | Average daily amount of caffeine consumption in mg | 24 hours | 
| Subgroup comparison between junior and senior anesthetists | Average daily amount of caffeine consumption in mg | 24 hours |
Evaluation of a Sarcopenia Prediction Model and Development and Effectiveness of a Nursing Guidance Mobile App

Study Overview
=================
Brief Summary
-----------------
We evaluated a model for the prediction of high-risk populations for sarcopenia in home settings, developed a sarcopenia nursing guidance mobile application, and assessed the effectiveness of this application in influencing sarcopenia-related knowledge and self-care behavior among participants.

Official Title
-----------------
Evaluation of a Sarcopenia Prediction Model and Development and Effectiveness of a Nursing Guidance Mobile App

Conditions
-----------------
Prediction of High-risk Populations for Sarcopenia

Intervention / Treatment
-----------------
* Device: sarcopenia nursing guidance mobile application was developed


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria were being a member of the public, aged ≥20 years and <80 years, and having experience using mobile devices or smartphones. Exclusion criteria were not belonging to a high-risk population for sarcopenia and/or being unable to use the application platform.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| one group<br>Using a one-group pretest-posttest design | Device: sarcopenia nursing guidance mobile application was developed<br>* The application enhanced participants' sarcopenia-related knowledge and awareness regarding self-care<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in sarcopenia-related knowledge and awareness regarding self-care | In this study, the mobile app significantly improved sarcopenia-related knowledge and awareness regarding self-care among the participants | 2019 2022 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
artificial intelligence, nursing, nursing guidance mobile application, prediction model, sarcopenia
Temperature and Analgesia Monitoring During Cardial Parmonary Bypass

Study Overview
=================
Brief Summary
-----------------
Investigator will apply IOC2 to reflect the depth of analgesic during hypothermia in CPB period. effectiveness of IOC2 monitoring for anesthetic depth versus commonly used vital sign monitoring based on factors such as blood pressure and heart rate. Evaluate the other sedation co-relation measurement, include BIS , IOC2 to reflected the consciousness during the operation. Evaluate the other hemodynamic index, include CO, SVV, CVP, PPV to reflect the circulation function , and the effect to the IOC2 and IOC1. Describe the trend of all the measurement. detect the variation of the index during the temperature change during the CPB.

Detailed Description
-----------------
In this study, Investigator will apply IOC2 to reflect the depth of analgesic during hypothermia in CPB period. Furthermore, investigator evaluated the effectiveness of IOC2 monitoring for anesthetic depth versus commonly used vital sign monitoring based on factors such as blood pressure and heart rate. Evaluate the other sedation co-relation measurement, include BIS , IOC2 to reflected the consciousness during the operation. Evaluate the other hemodynamic index, include CO, SVV, CVP, PPV to reflect the circulation function , and the effect to the IOC2 and IOC1. Describe the trend of all the measurement. detect the variation of the index during the temperature change during the CPB.

Official Title
-----------------
Temperature and Analgesia Monitoring During Cardial Parmonary Bypass

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: noninvasive analgesia measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: undergoing coronary artery bypass surgery Exclusion Criteria: change the surgery planning during the operation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: noninvasive analgesia measurement|noninvasive analgesia measurement using index of consciousness(IOC2)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IOC2 | Index of consciousness 2 | 1 DAY | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BIS | to monitor and compare appropriate conscious value | 1 DAY | 
| IOC1 | index of consciousness 1 | 1 DAY |
Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the new RIC regimen, containing of low dose of Bu (9.6mg/kg)and fludarabine without ATG, is suitable and effective in treating aged and/or intolerable patients with hematologic malignant disease, who undergoes allogenic stem cell transplantation.

Official Title
-----------------
The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases

Conditions
-----------------
Leukemia, Myelodysplastic Syndrome

Intervention / Treatment
-----------------
* Procedure: modified BuFlu conditioning


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed of hematologic malignant disease will undergo HLA matced HSCT age >=55years <55year and intolerable to standard myeloablative conditioning Exclusion Criteria: KPS status <70 cardiac EF<50% creatine clearance <50 ml/min ALT more than 10 times of upper normal limit

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| modified BuFlu, HSCT, elder/intolerable<br>The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning. | Procedure: modified BuFlu conditioning<br>* The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| stem cell engraftment |  | 30day post transplantation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| toxicity and treatment related mortality |  | 100day and 1 year post transplantation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Busulfan, Hematopoietic Stem Cell Transplantation, Fludarabine
Fear Among Dentists During COVID-19 Pandemic

Study Overview
=================
Brief Summary
-----------------
This study aimed to evaluate the anxiety and fear of infection between dentists working during the present corona virus disease 2019 (COVID-19) pandemic and to explore dentist's knowledge about various practice modifications and guidelines to fight the novel corona virus

Detailed Description
-----------------
The spread of corona virus (COVID-19) has posed significant challenges for dentistry and medicine, and dental and medical schools, in all affected countries. The speed of reaction and type of response to this disease around the world have been very variable according to differing healthcare systems, economies and political ideologies

Official Title
-----------------
Fear and Practice Modification Among Dentists During COVID-19 Pandemic

Conditions
-----------------
COVID

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dentist having bachelor of dentistry or equivalent degree Exclusion Criteria: paramedical staff and dental students

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fear among dentist during COVID 19 epidemic | measuring unit questionnaire and the measuring unit is categorical yes, no and unaware | 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| practice modification among dentist during COVID 19 epidemic | measuring unit questionnaire and the measuring unit is categorical yes, no and don't know | 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fear, practice modification, COVID-19, epidemic
A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers

Study Overview
=================
Brief Summary
-----------------
To test the safety and immunogenicity of rgp 120/HIV-1IIIB vaccine in HIV-1 seropositive adult patients.

Official Title
-----------------
A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Biological: rgp120/HIV-1IIIB


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have the following: Stage 1 or 2 Walter Reed clinical staging of HIV infected individuals. The ability to understand and sign a written informed consent form, which must be obtained prior to study entry. Be available for 24 weeks so that follow up may be completed. Qualify for care as Department of Defense health care beneficiary. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than HIV-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results. Concurrent Medication: Excluded: Corticosteroids or other known immunosuppressive drugs. Any experimental agents. Patients with the following are excluded: Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than HIV-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results. Prior Medication: Excluded within 30 days of study entry: Zidovudine or other anti-retroviral agents.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: rgp120/HIV-1IIIB|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vaccines, Synthetic, Drug Evaluation, Acquired Immunodeficiency Syndrome, AIDS Vaccines